These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

152 related articles for article (PubMed ID: 39289930)

  • 1. Recent Advances in the Linkers of Drug Conjugates.
    Deng S; Wen X; Wang J
    Curr Med Chem; 2024 Sep; ():. PubMed ID: 39289930
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Tandem-Cleavage Linkers Improve the In Vivo Stability and Tolerability of Antibody-Drug Conjugates.
    Chuprakov S; Ogunkoya AO; Barfield RM; Bauzon M; Hickle C; Kim YC; Yeo D; Zhang F; Rabuka D; Drake PM
    Bioconjug Chem; 2021 Apr; 32(4):746-754. PubMed ID: 33689309
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Sulfatase-cleavable linkers for antibody-drug conjugates.
    Bargh JD; Walsh SJ; Isidro-Llobet A; Omarjee S; Carroll JS; Spring DR
    Chem Sci; 2020 Jan; 11(9):2375-2380. PubMed ID: 34084399
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lysosomal-Cleavable Peptide Linkers in Antibody-Drug Conjugates.
    Balamkundu S; Liu CF
    Biomedicines; 2023 Nov; 11(11):. PubMed ID: 38002080
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Research advances in peptide‒drug conjugates.
    Gong L; Zhao H; Liu Y; Wu H; Liu C; Chang S; Chen L; Jin M; Wang Q; Gao Z; Huang W
    Acta Pharm Sin B; 2023 Sep; 13(9):3659-3677. PubMed ID: 37719380
    [TBL] [Abstract][Full Text] [Related]  

  • 6. ADME and Safety Aspects of Non-cleavable Linkers in Drug Discovery and Development.
    Walles M; Connor A; Hainzl D
    Curr Top Med Chem; 2017; 17(32):3463-3475. PubMed ID: 29357804
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Cleavable linkers in antibody-drug conjugates.
    Bargh JD; Isidro-Llobet A; Parker JS; Spring DR
    Chem Soc Rev; 2019 Aug; 48(16):4361-4374. PubMed ID: 31294429
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Development of Photoremovable Linkers as a Novel Strategy to Improve the Pharmacokinetics of Drug Conjugates and Their Potential Application in Antibody-Drug Conjugates for Cancer Therapy.
    Johan AN; Li Y
    Pharmaceuticals (Basel); 2022 May; 15(6):. PubMed ID: 35745573
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Weinheim Bergstr Ger; 2022 Mar; 134(13):e202114016. PubMed ID: 38505643
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Predictable and tunable half-life extension of therapeutic agents by controlled chemical release from macromolecular conjugates.
    Santi DV; Schneider EL; Reid R; Robinson L; Ashley GW
    Proc Natl Acad Sci U S A; 2012 Apr; 109(16):6211-6. PubMed ID: 22474378
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Azobenzene-Based Linker Strategy for Selective Activation of Antibody-Drug Conjugates.
    Xiao D; Liu L; Xie F; Dong J; Wang Y; Xu X; Zhong W; Deng H; Zhou X; Li S
    Angew Chem Int Ed Engl; 2024 Apr; 63(16):e202310318. PubMed ID: 38369681
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Engineering Enzyme-Cleavable Oligonucleotides by Automated Solid-Phase Incorporation of Cathepsin B Sensitive Dipeptide Linkers.
    Jin C; Ei-Sagheer AH; Li S; Vallis KA; Tan W; Brown T
    Angew Chem Int Ed Engl; 2022 Mar; 61(13):e202114016. PubMed ID: 34953094
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Linkers: An Assurance for Controlled Delivery of Antibody-Drug Conjugate.
    Sheyi R; de la Torre BG; Albericio F
    Pharmaceutics; 2022 Feb; 14(2):. PubMed ID: 35214128
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Disulfide based prodrugs for cancer therapy.
    Wang Q; Guan J; Wan J; Li Z
    RSC Adv; 2020 Jun; 10(41):24397-24409. PubMed ID: 35516223
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Mono-amino acid linkers enable highly potent small molecule-drug conjugates by conditional release.
    Zheng Y; Xu R; Cheng H; Tai W
    Mol Ther; 2024 Apr; 32(4):1048-1060. PubMed ID: 38369752
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Silyl Ether-Based Acid-Cleavable Antibody-MMAE Conjugates with Appropriate Stability and Efficacy.
    Wang Y; Fan S; Xiao D; Xie F; Li W; Zhong W; Zhou X
    Cancers (Basel); 2019 Jul; 11(7):. PubMed ID: 31288450
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Enzyme-Agnostic Lysosomal Screen Identifies New Legumain-Cleavable ADC Linkers.
    Miller JT; Vitro CN; Fang S; Benjamin SR; Tumey LN
    Bioconjug Chem; 2021 Apr; 32(4):842-858. PubMed ID: 33788548
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Stimuli-Responsive Prodrug Chemistries for Cancer Therapy.
    Bargakshatriya R; Pramanik SK
    Chembiochem; 2023 Sep; 24(18):e202300155. PubMed ID: 37341379
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Advances and Limitations of Antibody Drug Conjugates for Cancer.
    Mckertish CM; Kayser V
    Biomedicines; 2021 Jul; 9(8):. PubMed ID: 34440076
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Oxime-Linked Peptide-Daunomycin Conjugates as Good Tools for Selection of Suitable Homing Devices in Targeted Tumor Therapy: An Overview.
    Mező G; Gomena J; Ranđelović I; Dókus EL; Kiss K; Pethő L; Schuster S; Vári B; Vári-Mező D; Lajkó E; Polgár L; Kőhidai L; Tóvári J; Szabó I
    Int J Mol Sci; 2024 Feb; 25(3):. PubMed ID: 38339141
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.